Loading…
SCNI
Scinai Immunotherapeutics Ltd.
NASDAQ· Healthcare· Biotechnology· CUSIP 09073Q303
$2.51-6.34%Price as of Aug 29, 18:49 UTC · updated once a day, after the close
Key metrics
- Market cap
- $1.7M
- P/E
- 0.1x
- Forward P/E
- —
- P/B
- 0.1x
- Dividend yield
- —
- Payout
- —
- EPS
- $28.07
- ROE
- -26.53%
- Profit margin
- -174.78%
- Revenue growth
- +146.00%
- Beta
- 2.09
- 52-week high
- $16.80
- 52-week low
- $2.15
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.9% over 5Y.
today you would have $0.70▼ -99.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $7.12 | $33.45 | $59.50 | $296.00 | |
| P/S | — | 75343.3x | 173451.1x | — | — |
| P/B | — | 12189.9x | 11439.4x | — | — |
| EPS | $0.00 | $0.00 | -$160.00 | -$400.00 | |
| Profit margin | — | -633.64% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BBLGBone Biologics Corp | $0.62 | — | 0.3x | — | -54.96% | $1.69M |
| AEMDAethlon Medical Inc | $2.49 | — | 0.2x | — | -160.91% | $1.77M |
| SXTCChina SXT Pharmaceuticals, Inc. | $3.00 | — | 0.1x | — | -27.49% | $1.6M |
| MNDRMobile-health Network Solutions | $1.55 |
About the company
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
- 45
- Jerusalem, Israel
Company description provided by Yahoo Finance.